Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponsegromab PK/PD Study in Healthy Chinese Adults
NCT05685264Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2023
- Primary completion
- Jul 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ponsegromab in cancer cachexia (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Serum Concentration-Time Profile From Time 0 Extrapolated to Infinite Time at Day 127, Area Under the Serum Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration at Day 127 and 3 more. Started Jan 2023; status: completed.
02
Drugs
ponsegromab
03
Conditions
cancer cachexia
Beyond the preview
Go deeper on NCT05685264.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05685264.